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Background. Calcific uremic arteriolopathy (CUA) or calciphylaxis though generally noted for its highmortality, recent case reports
have shown promising results using single agent therapies. However, it is not clear whether combination therapeutic agents
will improve course of the disease. Objective. To determine clinical outcome in subjects with CUA on multimodal treatment.
Methods. All patients with end-stage renal failure (ESRF) at The Townsville Hospital, Australia, from April 1, 2006, to March
31, 2011, with diagnosis of CUA were retrospectively studied. Results. Six subjects with CUA (4 females and 2 males) were
on various combination therapeutic agents comprising sodium thiosulphate, hyperbaric oxygen, prednisolone, cinacalcet, and
parathyroidectomy in addition to intensified haemodialysis, specialist local wound care, and antibiotics. The wounds failed to heal
in 3 patients while 5 of the 6 subjects died; cause of death being sepsis in 3 and myocardial infarction in 2. Conclusion. Prognosis
of CUA remains poor in spite of multimodal combination therapy. Further prospective studies on a larger population are needed
to verify our findings.
1. Introduction
Calcific uremic arteriolopathy (CUA) or calciphylaxis is a
syndrome of painful skin necrosis and vascular calcification
with high morbidity and mortality. It occurs primarily
in patients with end-stage renal disease [1, 2]. Though
generally a rare syndrome, it is increasingly described in
subjects undergoing renal dialysis. Calciphylaxis has also
been described in subjects with normal renal function
including primary and secondary hyperparathyroidism [3,
4]. A common factor linking non-renal-failure-related pre-
sentation of the same disease is elevated parathyroid hor-
mone with or without elevated calcium-phosphate product
leading to calcification of small vessels. The consequences
of these are significant mortality of 80% principally from
multiple end organ damage due to ischemia and infarction
commonly complicated by infection; sepsis being the prin-
cipal cause of death [1–3]. Thus, traditional care addresses
the calcium-phosphate-PTH axis: substituting calcium with
non-calcium as phosphate binders, strict dietary phosphate
control, cautious vitamin D analogs, calcimimetics, and
surgical parathyroidectomy if necessary. Newer approaches
focus on intravascular and tissue mineralization: dissolution
of calcium deposits with the use of sodium thiosulfate,
altering osteoprotegerin, and NF-κB pathways with bispho-
sphonates [4, 5]. Recently, single agent treatment such as
sodium thiosulphate and hyperbaric oxygen has yielded
various successes in care of calciphylaxis [5–7]. Furthermore,
favourable outcome was recorded in limited reports on CUA
using cinacalcet or parathyroidectomy to achieve targeted
normalised calcium, phosphate, and parathyroid hormone
levels [8, 9]. Yet usefulness of these agents in the form of
combination therapy has not been fully explored [10, 11].
The aim of the study was to review all cases of CUA seen
in the last five years and determine its clinical course in the
setting of multimodality care.
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2. Material and Methods
All patients diagnosed to have CUA at The Townsville
Hospital, Australia, from April 1, 2006, to March 31,
2011, were retrospectively studied. Subjects with nonuremic
calciphylaxis were excluded from the study. Approval for the
study was sought from the hospital’s ethical committee. Data
collected included age, gender, onset of dialysis to diagnosis
of calciphylaxis, duration of the skin lesion, and outcome
defined as completely or partially healed skin lesions or
death of a subject. In all subjects, calciphylaxis trigger
agent(s) were ceased—calcium-based phosphate binders and
alphacalcidol; none was on warfarin. All the patients were on
oral erythropoietin for anemia in addition to iron infusion
in 2 patients. Primary cause of the renal failure was also
determined as well as comorbidities. Biochemical profile of
subjects with CUA at diagnosis and within 6 months on
multimodal care was recorded. These included corrected
calcium, phosphate, albumin, calculated calcium-phosphate
product, and parathyroid hormone.
The patients included in this study were reviewed by the
vascular team, and a second opinion was obtained from a
dermatologist. All lesions had a punch biopsy performed
across the ulcer edge, but if the specimen was insufficient
to demonstrate calciphylaxis, then a wedged biopsy was
performed to confirm the diagnosis. All biopsies were
analysed by the same pathologist; the diagnostic criteria used
were medial calcification of dermal small and medium-sized
arterioles and arteries, intimal fibroblastic and endothelial
proliferation associated with ischemic necrosis of subcuta-
neous adipose tissue, and epidermal ulceration. Medium-
sized arteries with medial calcific sclerosis (Monckeberg’s
medial calcific sclerosis) with no intimal or endothelial
proliferation were excluded from the study.
The patients’ wounds were managed by clinical occu-
pational and nurse therapist with specialist interest in
wound healing and compression therapy. The dry necrotic
lesions were gently hydrated to promote a moist wound
environment, encouraging autolytic debridement and cell
migration. An atraumatic dressing (silicone coated, Mepitel)
and nonadherent absorbent pad were applied as secondary
dressings. After autolytic debridement, a conformable silver
polymembrane was applied and retained with light tubular
support bandage. If the wound was infected, antibiotics were
administered based on microscopy, culture, and sensitivity
results following deep wound swab and blood cultures with
input from the infectious disease specialist. To improve
wound healing, daily hyperbaric oxygen was used in some
patients. Each treatment lasted 90 minutes undertaken at 2.4
atmospheres absolute (ATA).
Methods used in lowering calcium-phosphate product
and parathyroid hormone included emergency parathy-
roidectomy, use of non-calcium phosphate binders—
sevelamer 4.5 g/day—and cinacalcet 30mg daily. The latter
being calcimimetic lowers parathyroid hormone by increas-
ing sensitivity of the calcium receptor. All the patients had
low calcium containing dialysate (calcium concentration
1.25mEq/L) and the dialysis-dose was increased from 8 L
dialysate/day to 12 L/day. Oral prednisolone 50mg once daily
was administered in 2 patients due to contraindication to
parathyroidectomy and refusal to use sodium thiosulphate
(STS). Twenty-five grams of STS (100mL of a solution at
25% STS) were infused three times per week in 3 patients
for 1 to 3 months. The thiosulphate was administered imme-
diately after dialysis. There were no signs, symptoms, or elec-
trocardiographic evidence of hypocalcaemia at any time dur-
ing the course of STS therapy. There was no discernible effect
of each thiosulphate infusion on any of the plasma chemistry
values or any other adverse effects such as metabolic acidosis
or haemorrhagic complications. Wound response to the
treatments was monitored clinically and by serial photog-
raphy comparing before and after progress. In addition,
patients were followed up in outpatient clinics to determine
if the healed skin lesion relapsed or to determine cause of
death had the patient died. Treatment for comorbidities was
provided and followed up by the appropriate subspecialties.
Once discharged from the hospital, patients were fol-
lowed up weekly by the clinical occupational therapist
and by nephrologists 3 times a week at the renal dialysis
session looking for relapse of the calciphylaxis. Results were
presented in tabular form for all the patients. Comparison of
biochemical profile was made at and within 6 months after
the diagnosis of CUA with overall results depicted as mean±
standard deviation, where applicable.
3. Results
Over the five-year period, we recorded 6 cases of CUA out of
201 subjects who had regular haemodialysis sessions at the
unit as shown in Table 1. Of the 6 subjects, two-third was
females. Mean duration of dialysis was 20 months range 1 to
3 years. Infection was demonstrable in all subjects as revealed
by wound swab microscopy, culture, and sensitivity. The
commonest organism isolated was Pseudomonas aeruginosa
in 4 subjects, namely, patient 1, 4, 5, and 6. Patient 6 in addi-
tion had methicillin resistant Staphylococcus aureus (MRSA).
Patient 2 and 3 had MRSA and Klebsiella pneumonia, respec-
tively. Modalities of treatment of the calciphylaxis apart from
wound care and administration of antibiotics in all included
cinacalcet in patient 1, 3, and 6; prednisolone was used in
patient 3 and 4, while parathyroidectomy was emergently
done in patient 2 and 3 with marked hyperparathyroidism
and progressive disease despite medical therapy. Following
the parathyroid surgery, whereas patient 2 had her wounds
completely healed and remained in remission for 32 months,
patient 3 did not respond to the parathyroidectomy and
died 5 months later of sepsis. Below knee amputation was
performed in only one subject, patient 5, who did not
respond to local wound care, antibiotics, hyperbaric oxygen
therapy, and administration of sodium thiosulphate. The
CUA reoccurred rapidly within one week of the surgery
which was complicated by sepsis following withdrawal of fur-
ther treatment including haemodialysis. He died one month
after the knee amputation. Side effects of the treatments
offered were assessed, but none of the patients developed
any untoward effects to prednisolone, cinacalcet, STS, or
hyperbaric oxygen therapy. Overall, combination therapy for
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Table 1: Patients’ characteristics and clinical course in subjects with end-stage renal failure presenting with calciphylaxis.
Subject Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Age (years) 48 53 63 72 74 86
Gender Female Female Female Female Male Male
Cause of ESRF Diabetes Chronic GN Diabetes Diabetes Diabetes Obstructive uropathy
Duration RRT
(months)
12 36 24 21 15 12
Site of lesion Extensive∗ Distal Distal Extensive Distal Distal
Microorganism Pseudomonas MRSA Klebsiella Pseudomonas Pseudomonas MRSA+pseudomonas
Mode of therapy∗∗ Cinacalcet STS PTHX HBO
PTHX HBO STS
prednisolone
Cinacalcet
prednisolone
STS HBO
amputation
Cinacalcet HBO
Outcome Dead Dead Dead Dead Dead Alive
Cause of death Sepsis
Myocardial
infarction
Sepsis
Myocardial
infarction
Sepsis Not applicable
Comorbidities
DM ESRF IHD
HTN Asthma
Epilepsy ESRF gout DM ESRF gout
IHD DM ESRF
MGUS
DM ESRF
HTN arthritis
ESRF
Skin lesion outcome Failed Healed Failed Healed Failed Healed
Survival (months) 1 32 5 4 4 Alive
ESRF: end-stage renal failure, GN: glomerulonephritis, RRT: renal replacement therapy, ∗: extensive skin lesions involving the lower limbs, genitalia,
abdominal wall, and breast, MRSA: methicillin resistant Staph aureus, ∗∗: mode of therapy apart from general wound care and antibiotics, STS: sodium
thiosulphate, PTHX: parathyroidectomy, HBO: hyperbaric oxygen, IHD: ischemic heart disease, HTN: hypertension, MGUS: monoclonal gammopathy of
unknown significance.
Figure 1: Histology of skin biopsy of patient 4 showing calcific
arteriolopathy typical of calciphylaxis. Haematoxylin and eosin
stain, magnification 200x.
CUA was offered in the form of dual in 4 subjects, triple and
quadruple in one subject each as detailed in Table 3.
In addition to ESRF, other diseases were recorded
premorbidly. These include ischemic heart disease in subject
1 and 4 though patient 2 and 4 both died suddenly, and
autopsy confirmed myocardial infarction as a cause of death.
Other comorbidities apart from diabetes in all but 2 patients,
hypertension occurred in subject 1 and 5. Interestingly,
patient 2 and 3 were on treatment for gout. Closer look at
the survival details revealed only one patient is alive, the rest
died mainly within 9 months of diagnosis of CUA.
The histology of the skin biopsy of the patients was
analysed histologically as depicted in Figure 1. The defining
histological characteristic found in all the cases was extensive
calcification of small and medium-sized vessels of the
dermis and subcutis layer with typical calcific thrombo-
genic microangiopathy. The deposition of calcium in the
Figure 2: Successfully healed calciphylaxis following autolytic
debridement and dressings along with treatment with cinacalcet
and prednisolone in patient 4 who later died of myocardial
infarction.
media was either segmental or circumferential and was
accompanied by intimal hyperplasia, fibrosis, and thickening
with smooth muscle fibre atrophy. Table 2 shows mean
biochemical profile of subjects with CUA at diagnosis and
within 6 months after. Calcium-phosphate product was
similar in both groups, while serum parathyroid hormone
was significantly lower after the diagnosis.
Figure 2 shows completely healed ulcers of calciphylaxis
in patient 4 who had been on treatment for ischemic heart
disease. She presented initially with extremely painful leg
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Table 2: Comparison of biochemical profile of subjects with calciphylaxis at diagnosis and within 6 months after the diagnosis.
Test At diagnosis 3 to 6 months after diagnosis P value
Calcium (mmol/L) 2.3± 0.2 2.4± 0.2 NS
Phosphate (mmol/L) 2.0± 0.8 1.8± 1.0 NS
Ca× P (mmol/L) 4.5± 1.0 4.2± 1.8 NS
PTH (pmol/L) 80± 53 21± 17 <0.05
Albumin (g/L) 28± 7 26± 9 NS
SD: standard deviation, Ca× P: calcium-phosphate product, PTH: parathyroid hormone, NS: not significant.
Table 3: Multimodal care and outcome in subjects with calcific uremic arteriolopathy.
Patient Antibiotics Sodium Thiosulfate Cinacalcet Hyperbaric Oxygen Prednisolone Parathyroidectomy Outcome
1
√ √ √
Dead
2
√ √ √
Dead
3
√ √ √ √ √
Dead
4
√ √ √
Dead
5
√ √ √
Dead
6
√ √ √
Alive
ulcers with features of cardiac failure. Further echocardio-
graphic assessment revealed extensive coronary calcification
involving 3 main vessels. She was declared not for coronary
bypass grafting and opted for palliative care. She was on
the following oral agents: aspirin 100mg, clopidogrel 75mg,
nicorandil 20mg, isosorbide mononitrate 120mg, frusemide
40mg, atenolol 50mg, candesartan-hydrochlorothiazide
16/12.5mg, atorvastatin 40mg, and amlodipine 10mg all
were given once daily. Daily wound care and oral cinacalcet
along with prednisolone were commenced to which she
responded dramatically within one month and the lesions
completely healed by second month as shown in Figure 2.
She remained symptomatic of cardiac angina despite onmul-
tiple medications. Sadly, she died suddenly and autopsy con-
firmed myocardial infarction as the cause of death. On the
other hand, patient 1 had painful bilateral legs lesions which
progressed rapidly within a month with involvement of geni-
talia and breast. Sodium thiosulphate infusion and cinacalcet
were given for onemonth without improvement. The patient
declined further care and died of sepsis a week later following
discontinuance of active treatment including haemodialysis.
All the patients had ESRF on haemodialysis; two-third
due to diabetes. Other causes of ESRF recorded include
chronic glomerulonephritis and obstructive uropathy in one
subject each, respectively. All the subjects had lower limb
skin lesions. In addition, both patients 1 and 5 had proximal
involvement. The skin lesion partially healed in one subject
and failed to heal in the 3 who died of overwhelming sepsis.
On the other hand, the 2 subjects with successfully healed
wounds died of myocardial infarction 1 to 2 years later.
4. Discussion
We have demonstrated poor outcome of calciphylaxis in
subjects on multimodal combination therapies. All except
one patient died within an average of 9 months from the
diagnosis of the skin lesion; in line with others observation
[1, 2]. Recently, reports have shown high survival rate
and complete wound healing with the use of single agent
therapy including sodium thiosulphate, hyperbaric oxygen,
cinacalcet, and parathyroidectomy [5–9]. Surprisingly, such
benefit was not evident in our subjects on multiagent
treatment in the form of dual, triple, or quadruple therapies,
similar to Kyritsis et al. observation [10], but in contrast to
better outcome noted by Arenas et al. and by Baldwin and
colleagues [11, 12].
It is interesting to note that though single or multiple-
agent therapies aimed at lowering calcium-phosphate prod-
uct have shown some positive results in treatment of
calciphylaxis, to-date no standard management is univer-
sally accepted to treat this condition. Nonetheless, non-
calcium-containing phosphate binders, bisphosphonates, the
calcimimetic cinacalcet, and vitamin D analogs have been
used with this intent [13]. For instance, pamidronate, a
bisphosphonate used singly or in combination with other
agents, has been reported to respond favourably in subjects
with calciphylaxis [4, 14]. Similarly, by lowering serum
parathyroid hormone, cinacalcet has also proved to be
beneficial in care of CUA [15]. Furthermore, emergency
parathyroidectomy has been used in the treatment of patients
with CUA associated with hyperparathyroidism refractory
to medical therapy; however, case series have shown vari-
able results [1, 9, 16]. Other treatment modalities include
hyperbaric oxygen therapy which has been found useful
in management of CUA by improving tissue oxygenation
and promoting wound healing [7, 17]. Similarly, sodium
thiosulfate increases solubility of calcium deposits in CUA
with enhanced wound healing [6]. The success of sodium
thiosulfate therapy alone or in combination with other
agents in patients with calciphylaxis has been described in
several case reports and case series [5, 18, 19]. Despite the
observation by others of favourable outcome using multiple
agents in care of CUA, we recorded high mortality even after
successful wound healing.
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The factors attributable to the poor prognosis of CUA
in our series are not clear. Possible reasons for the high
mortality include delayed diagnosis due to low index of
suspicion emanating from alternative diagnosis, including
more common diabetic skin ulcer and osteomyelitis; both
conditions may coexist with the calciphylaxis itself [20].
Furthermore, other skin lesions such as vasculitis may mimic
calciphylaxis clinically including painful nonhealing ulcers
due to ischemia which might have led to delayed diagnosis.
However, with the high index of suspicion of CUA in our
cohort makes it less likely as a contributing factor. On the
other hand, site of CUA lesion has been reported to have
prognostic value. Some authors believe proximal localization
of the lesion to have worse prognosis [1, 21]. Interestingly,
only 2 of our subjects had proximal involvement yet 83%
of them died despite multi-interventional approach; in
agreement with others findings [1, 2]. Another confounding
prognostic factor is comorbidities. Five of the 6 subjects
studied had at least 3 other diseases apart from the CUA to
cope with. Furthermore, the cause of the calciphylaxis may
have prognostic significance. Nonuremic calciphylaxis tends
to have a less ominous course compared to those with ESRF
[3, 4] in support of high mortality in our study in which
all the subjects had renal failure from various aetiologies on
haemodialysis.
The major limitation of our study was small sample size
which limits power to detect associations reflecting relative
rarity of this condition in clinical practice. Furthermore, the
biochemistry profile presented was limited to at the time of
diagnosis and within 6 months after and did not address
daily changes which may have occurred in the course of
followup of the subjects. Nonuniformity of treatment of
calciphylaxis also makes it hard to conclude outcome as
poor as reported. Furthermore, contribution of other risk
factors of ischemic heart disease was not assessed in spite
of myocardial infarction being one of the common causes
of death in the study population. Lastly, it is important
to note that there is a limitation to retrospective studies
in general. Observations derived from such studies may
contain some missing information and thus may serve as
a stimulus to further prospective work to clarify findings.
The present work must be interpreted in the knowledge
of the defects inherent in such studies. Despite these, our
result is consistent with other reports [2, 10]. The study
has further suggested calciphylaxis, a syndrome with high
mortality irrespective of mode of care.
In conclusion, prognosis of CUA in subjects with ESRF
remains poor in spite of combination therapy and multi-
modality of wound care. Further prospective studies on a
larger population are needed to characterise our findings.
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